Characterization of Human Type C Enterotoxin Produced by Clinical *S. epidermidis* Isolates

Chimène Nanoukon 1,2, Dissou Affolabi 2, Daniel Keller 1, Rodrigue Tollo 2, Philippe Riegel 1, Lamine Baba-Moussa 3 and Gilles Prévost 1,*

1 Institut de Bactériologie, 3 rue Koebelé, Université de Strasbourg, CHRU Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, VBP EA 7290, F-67000 Strasbourg, France; chimnanouk85@yahoo.fr (C.N.); dkeller@unistra.fr (D.K.); riegel@unistra.fr (P.R.)
2 Laboratoire de Microbiologie du Centre National Hospitalier et Universitaire Hubert Koutoukou-Maga, Cotonou 01 BP 386, Benin; affolabi.dissou@yahoo.fr (D.A.); tollorodrigue@yahoo.fr (R.T.)
3 Faculté des Sciences et Techniques, Laboratoire de Biologie et de Typage Moléculaire en Microbiologie, Université d’Abomey, Calavi, Cotonou 05 BP 1604, Benin; laminesaid@yahoo.fr

* Correspondence: prevost@unistra.fr

Received: 5 March 2018; Accepted: 20 March 2018; Published: 27 March 2018

Abstract: Staphylococcal Enterotoxins (SEs) are superantigens (SAg) originally produced by *S. aureus*, but their presence in coagulase negative staphylococci (CNS) has long been suspected. This study aims to better characterize a novel C-like enterotoxin expressed by clinical *S. epidermidis* strains, called SEC<sub>epi</sub>. We isolated and characterized SEC<sub>epi</sub> for its molecular and functional properties. The toxin was structurally modeled according to its significant similarity with *S. aureus* SEC3. Most of SEC amino acid residues important for the formation of the trimolecular Major Histocompatibility Complex II MHCII–SEC–T Cell Receptor TCR complex are conserved in SEC<sub>epi</sub>. The functional properties of SEC<sub>epi</sub> were estimated after cloning, expression in *E. coli*, and purification. The recombinant SEC<sub>epi</sub> toxin exhibits biological characteristics of a SAg including stimulation of human T-cell mitogenicity, inducing and releasing high cytokines levels: IL-2, -4, -6, -8, -10, IFN-γ, TNF-α and GM-CSF at a dose as low as 3.7 pM. Compared to SEC<sub>aureus</sub>, the production of pro-sepsis cytokine IL-6 is significantly higher with SEC<sub>epi</sub>-activated lymphocytes. Furthermore, SEC<sub>epi</sub> is stable to heat, pepsin or trypsin hydrolysis. The SEC<sub>epi</sub> superantigen produced by CNS is functionally very close to that of *S. aureus*, possibly inducing a systemic inflammatory response at least comparable to that of SEC<sub>aureus</sub>, and may account for *S. epidermidis* pathogenicity.

Keywords: enterotoxins; superantigens; coagulase-negative staphylococci; *S. epidermidis*; mitogenicity; cytokines

Key Contribution: Enterotoxin C3-like from Staphylococcus *S. epidermidis* is a superantigen.

1. Introduction

Staphylococcal superantigens (SAgs) represent a large family of at least 23 members in *S. aureus* that includes toxic shock syndrome toxin-1 (TSST-1), staphylococcal enterotoxins (SEs), and SE-like (SEl) where emetic activities are lacking, not yet confirmed or whose roles in diseases remain under investigation [1–4]. SEs are common causes of food poisoning but were also involved in acute atopic eczema [5], urticaria [6] and rheumatoid arthritis [7]. Their involvement in lethal sepsis, infectious endocarditis, acute kidney injury and necrotizing pneumonia are also demonstrated in animal models [8,9]. These toxins are not only active on gastrointestinal and endothelial cells, but also function as superantigens that stimulate a non-specific but vigorous proliferation of T-cells bearing...
certain T Cell Receptor Vβ-chain variable regions [2,10]. This hyperstimulation occurs through the binding of enterotoxin to the α-helical regions of the Major Histocompatibility Complex class II (MHC-II) molecules present on antigen-presenting cells outside the peptide binding sites of the normal antigens [10]. Thus, conventional antigens stimulate 0.01% of T-cells, while SAgS can stimulate 30% or more of T-cells, according to individual specificities [10]. SEs superantigenicity induces many shared activities among which are cytokine induction, pyrogenicity, lymphocyte proliferation, immunosuppression, and toxic shock. Due to these properties, SEs are assumed to be a threat for public health.

In coagulase negative staphylococci (CNS), there are only few studies that demonstrate their ability to produce stable enterotoxins. Recent studies indicate that CNS isolated from veterinary sources and food may produce typically S. aureus-related SEs [11,12], but not CNS from human sources [13]. However, it has been recognized that superantigen genes are often associated with mobile genetic elements (MGEs), such as pathogenicity islands, prophages, or plasmids [14,15]. This suggests that SEs genes can move from S. aureus strain to strain by horizontal transfer and that the colonization of the skin and the mucosa, simultaneously by several Staphylococcus species might promote such genes transfer from S. aureus to skin commensal CNS. The sec gene encoding enterotoxin C has been reported among the most common enterotoxins observed in clinical S. aureus after, SEA, SED et SEB [16]. This toxin is produced by 16% of clinical S. aureus isolates [17]. Three major subtypes of SEC toxin (SEC1-3) exist. SEC3 differs from enterotoxins SEC1 and SEC2 by four and nine amino acids, respectively [16]. The three subtypes are immunologically close [18,19] and all activate T lymphocytes though T Cell Receptors (TCR) bearing hypervariable regions Vβs 3, 12, 13.2, 14, 15, 17 and/or 20 [20]. Nevertheless, it was shown that SEC2 and SEC3 have more affinity for TCR that bears Vβ 13.2 but bind more weakly TCR than SEC1 to TCR bearing Vβ3 [20]. This difference is due to a valine substitution at position 26 in SEC1 by a tyrosine in SEC2 and SEC3 [20]. In the CNS group, Staphylococcus epidermidis is one of the species that has attracted most attention by their involvement in serious hospital infections, particularly in cases related to prosthetic joint surgery [21,22]. A single human clinical S. epidermidis strain was previously characterized for carrying sec gene [23]. We previously reported the production of a staphylococcal enterotoxin C analogous in two new clinical S. epidermidis SE90 and SE95 isolates from Africa [24]. In the present study, we purified the novel type C-like enterotoxin produced by S. epidermidis named SECepi to determine its molecular, biological, and immunological characters as a preamble of its potential involvement in the pathogenicity of S. epidermidis.

2. Results

2.1. Characteristics of the Putative secepi Gene Encoded by Clinical S. epidermidis Strains

To examine the superantigenic capacity of the clinical S. epidermidis strains, we previously screened 22 S. epidermidis isolates from various clinical samples for enterotoxins genes (sea, seb, sec, seg and seh) by polymerase chain reaction (PCR) using specific primers. Two isolates (9%) from blood were found to carry and to express sec [24]. When using radial immunoprecipitation method and a standard range of purified toxin concentrations (data not shown), secepi is expressed at 60–90 µg/mL by both SE90 and SE95 isolates culture supernatants after 24 h of growth at 37 °C. The sec gene was sequenced from these two S. epidermidis isolates. Homology analysis of the deduced amino acids sequences of the amplified sec genes revealed that SECepi were 100% conserved among both two isolates, while analysis of the generated dendrogram issued from the MALDI-TOF spectrum of the 22 strains shows that both the two sec positive isolates strains do not aggregate in a single cluster (Figure 1). We amplified through PCR the corresponding Open Reading Frame (ORF) and sequenced the designated secepi encoding S. epidermidis staphylococcal enterotoxin-like toxin C (SECepi). The corresponding peptidic chain is 266 amino acids long for a structural gene of 801 bp (Figure 2). Thus, SECepi is closely-related to previously described SEs, albeit very efficiently secreted. Based on the results of homology comparison between the peptide chain of SECepi and known sec gene sequences, we found that secepi is close to...
S. aureus Mu3 sec3 gene, with three amino acids substitutions in the signal peptide (I7V, S21F, T22I), albeit efficiently secreted, and nine amino acids substitutions in the mature protein (S54N, K59N, K75N, G106S, V133I, N191S, M216I, N218K, T222M) (Figure 2). Furthermore, several SEC amino acid residues are important to the formation of the trimolecular MHC–SEC–TCR complex and, thus, promoting superantigenicity (amino acids for binding to TCR colored in red and amino acids for binding to MHC colored to pink), and conserved in the SECepi protein (Figure 2). We noted that only methionine 216, participating in the binding of MHC (surrounded by a pink frame) was substituted by an isoleucine in SECepi. Using the online signal peptide prediction software Expy Compute pI/Mw tool, we predicted the N-terminal amino acids sequence of the mature form of SECepi. The putative secreted protein sequence of SECepi has 239 amino acid residues with a predicted molecular weight of 27.6 kDa, and an isoelectric point at 6.35, while a disulfide bridge is formed, and, thus biochemical properties similar to those from S. aureus SEC.

Figure 1. Proteomic relatedness. Dendrogram generated by Biotyper™ based on MALDI-TOF spectral profiles of S. epidermidis isolates.

Figure 2. ClustalW alignment of amino acids sequences between S. epidermidis SEC3 (SEC3epi) and S. aureus Mu3 SEC3 (SEC3Mu3). Putative signal peptides are colored in yellow. The non-corresponding amino acids, amino acids required for binding to TCR Vβ chain and residues contacting MHC II (HLA-DR) are highlighted in grey, red and pink, respectively. The non-corresponding residue SECepi I216 to binding site of MHC is surrounded by a pink frame. Genomes of the S. epidermidis strains 90 and 95 are registered with the codes CP024408 and CP024437, respectively [25].
2.2. Structural Features of SEC\textsubscript{epi} and Structural Homology with SEC\textsubscript{aureus}

Using I-Tasser\textsuperscript{™} and WebLab ViewerPro\textsuperscript{™} software, we generated a predicted SEC\textsubscript{epi} 3D structure. The predicted conformation of SEC\textsubscript{epi} is characterized by unequal sized domains, as found too, in other bacterial superantigens. The larger domain top left is the \(\beta\)-grasp fold consisting of four to a five strand \(\beta\)-sheet over, which is in front of an \(\alpha\)-helix. The small domain bottom right is the fold of a Greek-key \(\beta\)-barrel capped by an \(\alpha\)-helix at its end and contains the disulfide loop (Figure 3A). A structural alignment of the predicted form of SEC\textsubscript{epi} with the previously determined structure of \textit{S. aureus} SEC type 3 in both I-TASSER\textsuperscript{™} software and in TM-align structural alignment program revealed that the amino acid residues involved in TCR and MHC bindings are structurally identical despite a M216I polymorphism (Figure 3B). A zinc coordination site is found in the structure of SEC\textsubscript{epi} and is coordinated by T36, D83, H118, H122 residues (Figure 3C). The zinc-binding site residues observed in the SEC\textsubscript{aureus} crystal structure (deposited in the Protein Data Bank with the accession code 1ck1) vary with the amino acid D9 replaced by T36. This clearly shows a high structural homology between the two isoforms.

![Figure 3. Prediction of the structure model of SEC\textsubscript{epi}, using I-Tasser\textsuperscript{™} and formatted through Weblab viewer Pro 3.7, and structural alignment and zinc binding sites; (A) Structure model of SEC\textsubscript{epi}. The predicted conformation was determined as “superantigen” in reference to its remarkable sequence. The resulting conformation is close to that of other superantigens 3D structures. The mutated amino acids are in ball and stick; (B) Structural alignment of SEC\textsubscript{epi}. Superimposition of the structure of SEC\textsubscript{aureus} (in line ribbon) with the predicted structure of SEC\textsubscript{epi} (in solid ribbon) shows that both toxins significantly matched together. The TCR binding sites (in yellow stick) and MHC binding sites (in pink stick) of both SEC isoforms are well superimposed. The mutated amino acid residues in SEC\textsubscript{epi} are colored in green ball and stick; (C) ligand binding sites of SEC\textsubscript{epi}, the zinc atom is represented as a green ball. Ligand binding sites residues identified in this study are colored in green stick.](image-url)
2.3. Expression and Purification of rSECepi

Transformation of the recombinant vector pGEX-secepi into E. coli BL21 allowed us to obtain three A1, A2 and A3 clones resistant to ampicillin. The expression of the fusion protein SECepi-GST in these clones was screened by SDS-PAGE after induction with the IPTG. The results showed that only clone A1 expresses SECepi by the presence of an approximately 53 KDa fusion protein of the GST (26 kDa) coupled to SECepi (27 kDa) (Figure 4A). After confirmation by nucleotide sequencing and peptide alignment with the SE90 and SE95 secepi gene amplicon sequences, recombinant SECepi was overexpressed in E. coli BL21 and purified by glutathione-Sepharose 4B chromatography. The immunological reactivities of rSECepi with rabbit affinity-purified S. aureus anti-enterotoxin C antibodies were assayed by using Western blot. As shown in Figure 4B, the antibody reacted with purified rSECepi. These results indicate that antigenic relationships of rSECepi are close to SECaureus.

![Figure 4. Analysis of cloning and identity of SECepi by 12% SDS-PAGE with Roti®-Blue staining.](image)

(A) SDS-PAGE 12% of the bacterial lysates of clones A1, A2 and A3 after cloning of secepi. The red arrow indicates the 53 kDa band corresponding to SECepi-GST expression by clone A1; (B) Immunoblotting of purified SECepi using rabbit affinity-purified S. aureus anti-enterotoxin C antibodies. Lane 1: Molecular weight standard, lane 2: 50 ng of rSECepi.

2.4. SECepi Is Stable to Heat Treatment and Digestive Enzymes Treatment

In this study, we examined whether SECepi resists to heat related to food preparation, pepsin, and trypsin digestion in gastrointestinal conditions. After heat treatment at 100 °C, 1–12 h, the samples were analyzed by SDS-PAGE (Figure 5A). The BSA band immediately disappeared before 1 h treatment. However, the SECepi and SECaureus bands persist after 1 h and before to become almost invisible at 2 h of treatment. For proteolytic enzymes analysis, the BSA band was no more visible 1 h after pepsin treatment. In contrast, the SECepi and SECaureus bands were still observed at up to 10 h after pepsin treatment and each showed a single band of equal intensity corresponding to its authentic size (27 kDa) (Figure 5B). Trypsin is the most important digestive protease in intestine of humans and animals. The stability of both enterotoxins upon trypsin digestion was further evaluated. SECepi and SECaureus treated with trypsin appeared as bands of molecular weight reduced by half (13 kDa) compared to the normal weight of the toxin in the SDS-polyacrylamide gels. However, these bands were observed until 12 h after treatment (Figure 5C). In contrast, trypsin-treated BSA appears as almost invisible bands already after 1 h (Figure 5C). Regarding the rate of hydrolysis, the trypsin
hydrolyzed products generated by SEC<sub>epi</sub> hydrolysis were identical to those generated from SEC<sub>aureus</sub>. This indicates that the mutations observed in the amino acid sequence of SEC<sub>epi</sub> do not affect its resistance to degradation by heat, or some of the harsh conditions of the gastrointestinal tract, at least.

**Figure 5.** Effects of heat and digestive enzymes treatment on SEC<sub>epi</sub> and SEC<sub>aureus</sub>. (A) enterotoxins (3.7 µM) were maintained at 100 °C. After the heat treatment, each sample was analyzed by SDS-PAGE; (B) Each protein at 3.7 µM was incubated with 0.028 µM of pepsin and analyzed by SDS-PAGE; (C) Each protein, at 100 µg/mL, was incubated with 0.04 µM of trypsin and analyzed by SDS-PAGE. BSA was used as negative control; NT, no treatment; P, pepsin; Tr, trypsin.

2.5. Functional Analyses of SEC<sub>epi</sub>

To examine the function of SEC<sub>epi</sub> in <i>S. epidermidis</i> pathogenicity from human, a recombinant protein was purified from <i>E. coli</i> and used to assess the superantigenic activity of enterotoxin. Lymphocyte proliferation and cytokines production were measured using human PBMC from three healthy donors. First, PBMC were stimulated in the presence or absence of various concentrations of rSEC<sub>epi</sub> and SEC<sub>aureus</sub>. SEC<sub>epi</sub> was tested for mitogenic activity on stimulated human PBMC in a 5-bromo-2′ deoxyuridine (BrdU) colorimetric incorporation assay [15]. Figure 6 shows representative results of three experiments. Addition of 100 U of polymyxin B as a LPS inhibitor did not influence the results, indicating that the effect due to LPS contamination was negligible (data not shown). The toxin strongly induces intense human T-cells proliferation at concentrations close to 3.7 × 10<sup>4</sup> pM (Figure 6),
but the protein was significantly mitogenic at doses as low as 3.7 pM. Interestingly, the superantigenic activity of SEC_epi in human T cells is comparable to that of *S. aureus* SEC (Figure 6A). Moreover, exposure of SEC_epi and SEC_aureus at 75 °C and 100 °C to other time intervals of 0–60 min after cells T stimulation shows a decrease of mitogenic effect according to time, albeit the toxin conserved a mitogenic potential after 1 h treatment at 100 °C (Figure 6B).

Figure 6. SEC_epi stimulates proliferation of human lymphocytes. (A) The proliferation of human PBMC activated with recombinant SEC_epi (orange bars) or SEC_aureus (blue bars) was measured by incorporation of 5-bromo-2′ deoxyuridine. Each bar represents the mean ± standard error of three independent experiments. Neg control: Negative control containing only PBMC; *** The results were significantly different in comparison with the negative control (*p* ≤ 0.001); (B) The proliferation of human PBMC activated with recombinant SEC_epi or SEC_aureus was measured by the incorporation of 5-bromo-2′ deoxyuridine after heat exposure at 75 °C and 100 °C according to time intervals of 0 to 60 min. The mitogenic activity of both toxins was significantly persisting after heating at 75 °C and 100 °C.

Second, the proinflammatory (IL-2, IL-6, IL-8, TNF-α, IFN-γ, GM-CFS) and suppressive cytokines (IL-4, IL-10) titer in human PBMC stimulated by SEC_epi was measured and compared with that stimulated by SEC_aureus (Figure 7). The results showed that compared to the negative control, SEC_epi induced a strong production of all cytokines tested with dose of toxin as low as
3.7 pM. The cytokines concentrations obtained in the supernatants varied according to the nature of cytokines tested. As examples, TNF-α, IFN-γ, IL-8, IL-6, IL-2 are produced at high titers of up to 8000 pg/mL, 7000 pg/mL, 7000 pg/mL, 3000 pg/mL and 2500 pg/mL, respectively, after activation of T cells with 3.7 pM of SEC_epi, while the same concentration of toxin stimulates the production of IL-10, GM-CSF, IL-4 to respective titers of 800 pg/mL, 500 pg/mL and 80 pg/mL (Figure 7). The comparison of cytokines production profile in human PBMC stimulated by SEC_epi with that of the wild-type (SEC_aureus) shows that there is no significant difference between released quantities of most cytokines induced by the two toxins, p > 0.05. However, the induction of pro-sepsis cytokine IL-6 is significantly higher in lymphocytes, when activated by SEC_epi (p ≤ 0.01). Moreover, the lymphocytes stimulated by 3.7 × 10^3 pM of SEC_epi are able to secrete up to 9–10 fold more IL-6 than those stimulated with the same amount of SEC_aureus (7500 pg/mL vs. 800 pg/mL, p ≤ 0.0001), suggesting that systemic inflammatory response induced by SEC_epi would be at least as severe than that caused by SEC_aureus.

**Figure 7.** Cytokines production in T cells activated with recombinant SEC_epi (orange line) or SEC_aureus (Blue line) in vitro. T cells (2 × 10^6 cells/mL) were prepared from three different donors and incubated for 72 h with concentrations ranging from 3.7 pM to 3.7 × 10^3 pM of SEC_epi or SEC_aureus. IL-2, IL-4, IL-6, IL-8, IFN-γ, TNF-α and GM-CSF production in the supernatants of the T cells culture were determined by an ELISA sandwich. The results are representative of three experiments.
3. Discussion

Although it was reported that acquisition of SE(s) gene(s) by CNS strains would be a rare or isolated event [26], the present study revealed that the SEs genes exist not only in a food poisoning isolate [1], but also in CNS isolates from cases of human infectious diseases. Indeed, this SECepi is produced at significant quantities in culture supernatant of some S. epidermidis isolates. This work reports a strong sequence similarity between C-types staphylococcal enterotoxin sequence of clinical strains of S. epidermidis SE90 and SE95 named SECepi from Africa and wide-type S. aureus SEC3. This level of sequence similarity served as a benchmark for the determination of the mature sequence of SECepi as well as its structure and the amino acid residues involved in the biological activity of this toxin. ClustalW analyses between SECepi and its isoform S. aureus SEC3 reveals an evolutionary signature corresponding to substitutions of several amino acids in the signal peptide and the secreted sequence of SECepi (I7V, S21F, T22I and S54N, K59N, K75N, G106S, V133I, N191S, M216I, N218K, T222M) (Figure 2). The prediction of the modeled SECepi structure produced an architecture close to the SEs [2,27] that has high structural homology with the predetermined structure of S. aureus SEC3 [28]. Moreover, the SE90 and SE95 SEC gene sequences is 100% identical to that of the FR909 strain isolated in the United States [24], albeit at least the two first isolates are not strictly identical. This suggests that similar mechanisms of molecular evolution and acquisition of the sec gene originally transcribed by S. aureus might occur in the genome of S. epidermidis isolates from different geographical areas, Africa and America.

Because SECepi exhibited a high degree of identity of amino acid sequence and ligand binding sites (Figures 2 and 3) with SECaureus, we hypothesized that both toxins have very close biological properties. Using a signal peptide predictor software, we identified the mature SECepi sequence which was then cloned into pGEX-6P-1. The resulting recombinant protein (rSECepi) was expressed and purified by affinity chromatography and the identity of the protein is confirmed by Western blot method as a ~27 kDa protein using rabbit affinity-purified S. aureus anti-enterotoxin C antibodies (Figure 4B) [28]. SEs are well-known to resist heating and digestive enzymes [28–30]. rSECepi was able to keep 30% function after heating at 100 °C for 1 h as SECaureus does (Figures 5 and 6), more or less, but it was less resistant than SEA, which resists beyond 8 h of heat treatment [15]. In the case of gastrointestinal enzymes, the toxin was stable to pepsin and slightly unstable to trypsin action. There was no major alteration in SECepi susceptibility to pepsin and trypsin hydrolysis compared with the native SECaureus. A comparison between the proteolytic enzyme stability of SECepi and SEA, the most studied enterotoxin, showed that SECepi is less resistant to trypsin activity than SEA, but has the same pepsin resistance profile as SEA [30]. In our previous study, 9% (2/22) of S. epidermidis clinical isolates originating from Benin secreted a functional SEC parent [24]. This frequency is even greater than in other reports, where only 3% (1/32) of S. epidermidis strains from food produced a stable enterotoxin C, while none of 200 clinical strains produced it [11,27]. In one of our studies involving 30 S. epidermidis strains from a significant clinical origin collected in the Microbiology laboratory of the Strasbourg hospital, there was no positive strain for the sec gene. However, approximately 16% of clinical S. aureus strains are producing SECaureus [17].

rSECepi, which shows homology to SECaureus, acts as a superantigen for human T lymphocytes because of its ability to induce lymphocytes proliferation and cytokines production from human T cells already with a low dose of the toxin (3.7 pM) (Figures 6 and 7). Substantial amounts of proinflammatory cytokines such as TNF-α, IFN-γ, IL-8, IL-6, IL-10 and IL-2 were found in the isolated human T lymphocytes culture supernatants activated with SECepi, while they were almost not detected in the culture supernatant of unactivated cells. Moreover, IL-6, which is an important mediator of the systemic inflammatory response in septic shock, is produced at a higher level in the culture supernatants of SECepi stimulated T cells [31,32]. In fact, high levels of IL-6 were found to predict a fatal outcome in patients with septic shock [33]. This increased cytokine concentration may accentuate the intensity of the immune response and result in a systemic shock leading to disseminated intravascular coagulation that can lead to hemorrhage, severe coagulation disorders and to the failure of organs,
eventually leading to death [34]. The ability of rSECepi to stimulate human lymphocytes implies that this enterotoxin can bind to TCR Vβ elements and/or MHC class II molecules in the human [2]. In previous studies, several amino acid residues important for binding to TCR Vβ and MHC class II elements to SEC have been identified [35–37]. Except polymorphism at M216I, not any mutation of the involved amino acids is present in the peptide sequence of SECepi (Figure 3B), and this would support the preservation of the superantigenic activity of the secreted enterotoxin as well as the TCR Vβ epitope segregation. It remains hypothetical whether the substitution of Methionine at position 216 by Isoleucine in SECepi TCR Vβ binding site, is involved in a variation in the amount of IL-6 produced by the activated lymphocytes. We also found that through the binding area, which forms the zinc binding site of SECaureus, only D9 of S. aureus is replaced by T36 in SECepi zinc binding amino acid residues sites (Figure 3C). A previous report noted that zinc binding is not essential for T cell stimulation, emesis, or lethality in SEC sub-types [27]. These findings are consistent with the fact that a mutation occurring at the usual zinc binding sites in SECepi does not alter its functions, as observed for S. aureus enterotoxin C2 [38].

Moreover, in this study, S. epidermidis SE90 and SE95 produced up to 100 µg/mL of staphylococcal enterotoxin C in 24 h at 37 °C of microbial broth culture. This dose largely exceeds the quantities of SECaureus found in 24 h culture supernatants (BHI) of S. aureus isolates FRI137 (296 ng/mL), FRI913 (4134 ng/mL) and a food strain, S. epidermidis 4 s (14 ng/mL) in another study [11]. Therefore, it might be possible that a similar amount of Secepi may be secreted in food contaminated with enterotoxigenic S. epidermidis since, in most of the food poisoning cases caused by SEs produced by S. aureus, where amounts ranging from 5 to 100 ng/g enterotoxins can be detected in the associated foods [39]. This suggests that SECepi would also be able to trigger a food poisoning outbreak. In addition, heating at 75 °C and 100 °C did not inhibit the activity of the toxin but could reduce their mitogenic effect on T cells.

These results, together with our previous data, demonstrate that clinical strains of CNS can also carry dreaded virulence factors in S. aureus, including the staphylococcal enterotoxin C. This study not only suggests a structural similarity between SECepi and SECaureus but also provides proof that SECepi may act as a superantigen in the human host although SEC wild-type carries several differences in S. epidermidis. Given the great similarity between SECaureus and SECepi, the ability of SCN to produce enterotoxins in significant quantities also poses a real problem for food safety and may be some clinical cases. It now remains interesting to study in vivo toxicity and emetic activity of SECepi, because the International Nomenclature Committee for Staphylococcal Superantigens [40] proposed that only staphylococcal superantigens inducing emesis after oral administration in an experimental model of primates should be designated as staphylococcal enterotoxins.

4. Materials and Methods

4.1. Ethical Statement

Buffy coats from fresh human blood from healthy donors were purchased from the « Etablissement Français du Sang de Strasbourg, France », for which all individual information remains confidential.

4.2. Bacterial Strains, Vectors Media, and Growth Conditions

S. epidermidis strains were clinical isolates originated from blood samples and identified with MALDI-TOF Biotyper™ (Bruker Daltonics) and 16S rDNA genes sequencing [24]. Dendograms were generated from main spectra projection using MALDI/TOF MS Microflex™ system and Biotyper™ software. Each S. epidermidis isolate was previously screened for SEA, SEB, SEC, SEG, and SEH by Western blot and immunodiffusion techniques [24]. S. epidermidis isolates that were called SE90 and SE95 were found to produce SEC and were chosen for further analysis of the enterotoxin. S. aureus SCP FRI 361 strain, a SEC producer was used as a positive control to verify the purified recombinant protein identity.
Escherichia coli XL1 blue cells [recA1 endA1 gyrA96 thi1 hsdR17 supE44 relA1 lac (F′ proAB lacIqZΔM15 Tn10 (tetr))] (Stratagene, Agilent technologies, Massie, France) were used as recipient cells for transformation with recombinant pGEX-6P-1-sec_epi gene (GE healthcare life science, Buc, France). Escherichia coli BL21 [F–, ompT, hsdS (rB–, mB–), gal] was used for over-expression of the glutathione-S-transferase (GST)-S. epidermidis enterotoxin C fusion gene, according to the manufacturer’s (GE healthcare).

For routine culture, bacteria were grown on Columbia blood agar plates (Oxoid). Overnight cultures were prepared in tryptone broth containing 4% yeast extract (Oxoid). 2% yeast extract-trypton broth (YT) was used for culturing E. coli BL21, E. coli XL1 and E. coli transformants. All cultures were incubated in an aerobic atmosphere at 37 °C.

4.3. DNA Isolation

Total DNA of S. epidermidis was purified using MasterPure™ DNA Purification according to the manufacturer’s recommendations (Epicentre, Le Perray en Yvelines, France). DNA purity was checked by a 260/280 ratio and samples with ratios < 1.8 were rejected. EZ-10 spin miniprep kit (Euromedex, Souffelweyersheim, France) was used for amplicons purification following the manufacturer’s instructions. For plasmid DNA isolation, E. coli XL-1 plasmid DNA midi-preparation was performed with GeneJET™ Midiprep Kit (Thermo Scientific, Illkirch-Graffenstaden, France).

4.4. Nucleotide Sequencing and Analysis

Nucleotide sequencing of sec gene from S. epidermidis SE90 and SE95 (sec_epi) and recombinant sec_epi gene was determined by sequencing through Sanger methods employing the dideoxynucleotide sequencing methodology [41]. Briefly, the sec_epi gene was amplified by PCR for the two strains of S. epidermidis sec+. Cinq µL (60 ng/µL) of purified amplicon were supplemented by 5 µL of oligonucleotide (5 µM) and sent to GATC (GATC BIOTEC, Konstanz, Germany) for sequencing.

The plasmid containing the intact sequence of rsec_epi was purified after E. coli xl1 plasmid DNA midi-preparation. Ten microliters (80–100 ng/mL) of purified plasmid were added to 5 µL (5 pM) of each primer in a tube of 0.5 mL and sent for sequencing (GATC Gmbh, Konstanz, Germany).

4.5. Bioinformatic Analysis

Sequence databases were searched with the blast program available https://blast.ncbi.nlm.nih.gov/blast.cgi. The sequence alignments were performed using the Clustalw2 alignment software (http://www.ebi.ac.uk/tools/maa/clustalw2/). The DNA sequences were translated to ORF by expasy translate [42]. The molecular weight and isoelectric point (pI) were predicted by the protParam server [43]. The modeled structure and protein ligand binding site residues of SEC_epi were predicted using the I-TASSER server (Iterative Threading ASSEmbly Refinement) in Michigan University [44]. The modeled SEC_epi was used for comparison with predetermined structure SEC derived from S. aureus.

4.6. Cloning of sec_epi Gene

The gene fragment corresponding to the mature form of sec_epi gene was amplified from S. epidermidis SE90 DNA using the Phusion High-Fidelity DNA Polymerase (Thermo Scientific, Illkirch-Graffenstaden, France) according to the protocol: 94 °C for 3 min, followed by 30 cycles at 92 °C for 2 min, 50 °C for 1 min, 72 °C for 2 min. The cloning primers including a 5’_BamHI site, 5’_GAGTCAACCGAGCCTATGCGAGA_3’ and 5’_EcoRI site, 5’_AAGTTTATCCATTCTTTGGTGAAGGT_3’. The amplicon was purified using EZ-10 Spin Column PCR products purification Kit (EUROMEDEX, Souffelweyersheim, France) and DNA fragment digested by BamHI and EcoRI was then subcloned into the pGEX-6P-1 glutathione S-transferase (GST) fusion expression vector (GE Healthcare, Buc, France). The plasmid containing the intact sequence of the respective region of sec_epi was transformed into Escherichia coli XL-1 blue, and the insertion of the proper length restriction
fragment was verified by plasmid sequencing. The resulting recombinant SEC_epi had 5 additional amino acid residues (GPLGS) at the N terminus from pGEX-6P-1. Plasmid DNA midi-preparation was performed, and recombinant plasmid was inserted in *Escherichia coli* BL21 for SEC_epi expression and purification.

### 4.7. Expression and Purification of rSEC_epi

The recombinant clone was used for expression of the gene. Briefly, *Escherichia coli* BL21 harboring recombinant pGEX-6P-1 was grown in 2xTY broth containing 100 µg of ampicillin/mL at 35 °C to an optical density at 600 nm of 0.5. The expression of the GST fusion protein was induced by adding 0.2 M IPTG (isopropyl-D-thiogalactopyranoside, Amersham) to a final concentration of 0.2 mM. After 16 h of cultivation at 27 °C, the cells were harvested and lysed by French Press (French Pressure Cell Press, SLM AMINCO®). The clarified lysate was purified by affinity chromatography by using Glutathione Sepharose™ 4B (GE Healthcare, Buc, France). The GST fusion SEC_epi was eluted with 10 mM glutathione in 50 mM Tris-HCl (pH 8.0). Mature-form toxins were then released by digestion for overnight at 4 °C with PreScission Protease (GE Healthcare, Buc, France), which cleaves at a single site between the GST tag and the mature form SEC_epi. The protease and the GST tag was separated by passing the samples through glutathione-sepharose 4B. Purification of rSECepi through a cation-exchange chromatography (40 mM MES, 1 mM DTT, pH 5.7) was further achieved using a NaCl gradient from 0 to 250 mM, to eliminate LPS traces. Purity was verified in Roti®-Blue quick-stained sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (12% (w/v)) in agarose gel (0.6% (w/v) of agarose in PBS) against purified *S. aureus* SEC antigens. The protein concentration was assessed by using the Bradford assay (Bio-Rad), Bovine Serum Albumine for calibration and pure mature rSEC_epi was stocked at −80 °C until used for biological and biochemical assays.

The recombinant SEC from *S. aureus* was obtained from *S. aureus* FRI137 as described in patent PCT/IB2012/050909.

### 4.8. Western Blotting

Purified recombinant protein identity was assess by western blotting as describe [45]. Briefly, the protein concentration was measured using the Bradford reagent (BioRad, Steenvoorde, France) and 50 ng of protein was loaded per well in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (12% polyacrylamide) and transferred to Immobilon-membranes (TransBlot® Turbo™, BioRad, Steenvoorde, France) using the manufacturer’s instructions. After being blocked with 3% bovine serum albumin in phosphate buffered saline (PBS) supplemented with 0.05% (v/v) Tween 20, membranes were incubated with rabbit affinity-purified anti-*S. aureus* enterotoxin C antibodies (primary antibody) [29,45]. To detect the primary antibody, a goat peroxidase-conjugated anti-rabbit IgG (Sigma-Aldrich, Saint Quentin-Fallavier, France) were used. Proteins were visualized using 4-chloronaphtol (Opti4CN) detection kit according to the manufacturer’s directions (BioRad, Steenvoorde, France).

### 4.9. Determination of Enzyme and Heat Stability of SEC_epi

SEs stability assays to heat and gastrointestinal environment were performed as reported previously [30]. Bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) and purified *S. aureus* SEC was used respectively as a protein negative control and positive control.

To study the stability of purified protein against heat treatment, 300 µL of the toxin at 3.7 µM in PBS was placed into a heat block maintained at 100 °C. At desired time intervals ranging from 1 to 10 h, tubes were removed from the heat block, immediately put into an ice bath for 5 min to cool down, and then placed at −20 °C.

Purified SEC_epi, *S. aureus* SEC or BSA, was incubated in the presence of trypsin (Sigma-Aldrich, Saint Quentin-Fallavier, France). Each protein at 3.7 µM was incubated with trypsin (0.04 µM) in 0.01 M Tris-HCl, pH 8.0 in a final volume of 300 mL at 37 °C. After incubation for the desired periods
of time ranging from 1 to 10 h, tubes were removed and digestion is stopped by treatment at 95 °C for 5 min. Tubes were immediately stored at −20 °C.

Purified SEC_{epi}, *S. aureus* SEC or BSA was incubated in the presence of pepsin (Sigma-Aldrich, city, France). Each protein at 3.7 µM was incubated with pepsin (0.028 µM) in a final volume of 300 µL of 0.1 M sodium acetate buffer, pH 4.0, at 37 °C. After incubation for the desired periods of time intervals ranging from 1 to 10 h. Tubes were removed, and digestion is stopped by treatment at 95 °C for 5 min. Tubes were immediately stored at −20 °C.

4.10. Human Peripheral Blood Mononuclear Cells (hPMBC) Purification and Culture

hPMBC were obtained from samples of heparinized whole blood by centrifugation through a Ficoll-Paque gradient (blood diluted in PBS–Ficoll, 6:4 v/v [46]. PMBC were resuspended in RPMI 1640 for washing and then recovered by an 800 × g centrifugation at RT. The cells were resuspended in RPMI medium supplemented with 10% fetal bovine serum, 2 mM de glutaMAX and 0.1% de penicillin/streptomycin. The PMBC were resuspended in 25 mL of complete RPMI, plated in Petri plates, and allowed to incubate 3 h at 37 °C (5% CO₂). The non-adherent T lymphocyte-enriched cells were collected and washed.

4.11. Cell Proliferation Assays

4.11.1. Cell Proliferation with Different Concentrations of SEC_{epi} and SEC_{aureus}

To assess the mitogenic capacity of toxin, we used the cell proliferation ELISA, BrdU (5-bromo-2-deoxyuridine) colorimetric assay (Roche, Meylan, France) according to the Manufacturer’s recommendations. The purified hPMBC (2 × 10^6/mL, 0.2 mL) were stimulated with rSEC_{epi} or *S. aureus* SEC at concentration of 3.7 to 3.7 × 10^4 pM at 37 °C and with or without 100 U of polymyxin B sulfate [Sigma, France/mL, a lipopolysaccharide (LPS) inhibitor] in a 5% CO₂ incubator. After incubation for 48 h, microplates were supplemented with 10 µM BrdU for 16–24 h. Cell proliferation was estimated by incorporation of BrdU measurement into newly synthesized cell DNA. They were fixed with 200 µL of FixDenat in a microplate for 30 min at 15–25 °C before cells were softly sedimented and resuspended in 100 µL of dividing cells using peroxidase-conjugated anti-BrdU antibodies as recommended by the Manufacturer. After 1 h at room temperature and 3 washes with PBS, the cells are supplemented with TMB. The reaction is stopped after 15 min with H₂SO₄ and the absorbances are measured in ELISA reader at 450 nm/690 nm. Data are presented as means of triplicate determinations, as previously described [15].

4.11.2. Cell Proliferation after Toxins SEC_{epi} and SEC_{aureus} Heating

SEC_{epi} et SEC_{aureus} were diluted at 100 ng/mL in PBS, then heated at 75 °C or 100 °C for 0, 30 or 60 min. Heating effect was evaluated onto the hPBMC-derived T lymphocytes proliferation as described above (2.11.1) in the presence of 37 pM of SEC_{epi} or SEC_{aureus} according time and heating temperature in triplicate onto independent sources of cells, using the BrdU test. Proliferation is expressed as the absorbance ratio: (DO450/690 assay – DO450/690 control = derived T lymphocytes only).

4.12. Screening for Cytokines Production by Activated T Cells

Cytokines interleukin −2 (−2, −4, −6, −8, −10), gamma interferon (IFN-γ), Tumor Necrosis Factor-α (TNF-α) and Granulocyte macrophage colony-stimulating factor (GM-CSF) production in human PBMCs-derived T lymphocytes stimulated by SEC_{epi} and SEC_{aureus} was measured to assess superantigenic activity. Briefly, hPBMCs-derived T lymphocytes were stimulated with 3.7 to 3.7 × 10^3 pM of purified SEC_{epi}. The cells were incubated at 37 °C for 72 h in a humidified 5% CO₂ atmosphere. Culture supernatants were harvested by centrifugation to cytokine assays. The production of cytokine is determined using Bio-Plex Pro® Human Cytokines 8-plex Assay kit from Bio-Rad Laboratories, Inc. with magnetic beads, and a Bio-Plex 100® System and Bio-Plex
Manager® software version 6.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to manufacturer’s instructions. Briefly, beads were incubated for 20 s on 96 well plates and were washed in Bio-plex wash buffer. Diluted standard and samples were added, and the plates were incubated for 30 min on shaker. After washing, detection antibodies were added and reincubated for 30 min on shaker. The plates were washed and streptavidin-phycoerythrin (SA-PE) added, followed by 10 min of incubation and wash. Assay buffer was finally added and incubated for 10 min, followed by the plates analyzed. Data are presented as the means of standard deviations of triplicate determinations.

4.13. Statistical Analysis

Data are presented as mean ± standard deviation from three independent experiments performed in triplicate. The χ² test was carried out with the Minitab 14 (https://www.minitab.com/academic/) for proportions comparison and the level of significance was set at p values < 0.05 for all tests.

Acknowledgments: Chimène Nanoukon was awarded by the Islamic Bank for Development. We thank research grant from EA7290 Virulence Bactérienne Précoce, Faculté de Médecine (University of Strasbourg) and the Islamic Bank for Development.

Author Contributions: Chimène Nanoukon conducted all practical experiments, bioinformatic assays, all data analysis and writing the manuscript. Rodrigue Tollo and Dissou Affolabi, Philippe Riegel participated to collection and identification of strains of S. epidermidis. Daniel Keller contributed to gene cloning and expression and toxins purification. Gilles Prevost and Lamine Baba-Moussa supervised the project and contributed in preparation of the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Spaulding, A.; Salgado-Pabón, W.; Kohler, P.; Horswill, A.; Leung, D.; Schlievert, P. Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 2013, 26, 422–447. [CrossRef] [PubMed]
2. Argudín, M.A.; Mendoza, M.C.; Rodicio, M.R. Food poisoning and Staphylococcus aureus enterotoxins. Toxins 2010, 2, 1751–1773. [CrossRef] [PubMed]
3. Vu, B.G.; Stach, C.S.; Salgado-Pabon, W.; Diekema, D.J.; Gardner, S.E.; Schlievert, P.M. Superantigens of Staphylococcus aureus from patients with diabetic foot ulcers. J. Infect. Dis. 2014, 210, 1920–1927. [CrossRef] [PubMed]
4. Hennekinne, J.A.; Buyser, M.L.; Dragacci, S. Staphylococcus aureus and its food poisoning toxins: Characterization and outbreak investigation. FEMS Microbiol. Rev. 2012, 36, 815–836. [CrossRef] [PubMed]
5. Mempel, M.; Lina, G.; Hojka, M.; Schnopp, C.; Seidl, H.P.; Schafer, T.; Ring, J.; Vandenesch, F.; Abeck, D. High prevalence of superantigens associated with the egc locus. In Staphylococcus aureus isolates from patients with atopic eczema. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22, 306–309. [PubMed]
6. Ye, Y.M.; Hur, G.Y.; Park, H.J.; Kim, S.H.; Kim, H.M.; Park, H.S. Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria. J. Korean Med. Sci. 2008, 23, 845–851. [CrossRef] [PubMed]
7. Bunning, V.K.; Lindsay, J.A.; Archer, D.L. Chronic health effects of microbial foodborne disease. World Health Stat. Q. 1997, 50, 51–56. [PubMed]
8. Salgado-Pabón, W.; Breshears, L.; Spaulding, A.R.; Merriman, J.A.; Stach, C.S.; Horswill, A.R.; Peterson, M.L.; Schlievert, P.M. Superantigens are critical for Staphylococcus aureus infective endocarditis, sepsis, and acute kidney injury. MBio 2013, 4, e00494-13. [CrossRef] [PubMed]
9. Wilson, G.J.; Seo, K.S.; Cartwright, R.A.; Connelley, T.; Chuang-Smith, O.N.; Merriman, J.A.; Guinane, C.M.; Park, J.Y.; Bohach, G.A.; Schlievert, P.M.; et al. A novel core genome-encoded superantigen contributes to lethality of community-associated MRSA necrotizing pneumonia. PLoS Pathog. 2011, 7, e1002271. [CrossRef] [PubMed]
10. Dinges, M.M.; Orwin, P.M.; Schlievert, P.M. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 2000, 13, 16–34. [CrossRef] [PubMed]
11. Podkowik, M.; Seo, K.S.; Schubert, J.; Tolo, I.; Robinson, D.A.; Bania, J.; Bystron, J. Genotype and enterotoxigenicity of Staphylococcus epidermidis isolate from ready to eat meat products. *Int. J. Food Microbiol.* **2016**, *229*, 52–59. [CrossRef] [PubMed]

12. Veras, J.F.; Carmo, L.S.; Tong, L.C.; Shupp, J.W.; Cummings, C.; Santos, D.A.; Cerqueira, M.M.O.; Cantini, A.; Nicolli, J.R.; Jett, M. A study of the enterotoxigenicity of coagulase negative and coagulase-positive staphylococcal isolates from food poisoning outbreaks in Minas Gerais, Brazil. *Int. J. Infect. Dis.* **2008**, *12*, 410–415. [CrossRef] [PubMed]

13. Stach, C.S.; Vu, B.G.; Schlievert, P.M. Determining the presence of superantigens in coagulase negative staphylococci from humans. *PLoS ONE* **2015**, *10*, e0143341. [CrossRef] [PubMed]

14. Sato’o, Y.; Omoe, K.; Ono, H.K.; Nakane, A.; Hu, D.L. A novel comprehensive analysis method for *Staphylococcus aureus* pathogenicity islands. *Microbiol. Immunol.* **2013**, *57*, 91–99. [CrossRef] [PubMed]

15. Ono, H.K.; Sato’o, Y.; Narita, K.; Naito, I.; Hirose, S.; Hisatsune, J.; Asano, K.; Hu, D.L.; Omoe, K.; Sugai, M.; et al. Identification and characterization of a novel staphylococcal emetic toxin. *Appl. Environ. Microbiol.* **2015**, *81*, 7034–7040. [CrossRef] [PubMed]

16. Balaban, N.; Rasooly, A. Staphylococcal enterotoxins. *Int. J. Food Microbiol.* **2000**, *61*, 1–10. [CrossRef]

17. Wieneke, A. Enterotoxin production by strains of *Staphylococcus aureus* isolated from foods and human beings. *J. Hyg.* **1974**, *73*, 255–262. [CrossRef] [PubMed]

18. Marr, J.C.; Lyon, J.D.; Roberson, J.R.; Lupher, M.; Davis, W.C.; Bohach, G.A. Characterization of novel type C staphylococcal enterotoxins: Biological and evolutionary implications. *Infect. Immun.* **1993**, *61*, 4254–4262. [PubMed]

19. Reiser, R.F.; Robbins, R.N.; Noleto, A.L.; Khoe, G.P.; Bergdoll, M.S. Identification, purification, and some physicochemical properties of staphylococcal enterotoxin C3. *Infect. Immun.* **1984**, *45*, 625–630. [PubMed]

20. Deringer, J.R.; Ely, R.J.; Stauffacher, C.V.; Bohach, G.A. Subtype-specific interactions of type C staphylococcal enterotoxins with the T-cell receptor. *Mol. Microbiol.* **1996**, *22*, 523–534. [CrossRef] [PubMed]

21. Otto, M. *Staphylococcus epidermidis*—The “accidental” pathogen. *Nat. Rev. Microbiol.* **2009**, *7*, 555–567. [CrossRef] [PubMed]

22. Ziebuhr, W. *Staphylococcus aureus* and *Staphylococcus epidermidis*: Emerging pathogens in nosocomial infections. *Contrib. Microbiol.* **2001**, *8*, 102–107. [PubMed]

23. Madhusoodanan, J.; Seo, K.S.; Park, J.Y.; Gill, A.L.; Waterhouse, J.; Remortel, B.; Bohach, G.; Gill, S.R. *Abstract of 107th General Meeting of the American Society for Microbiology, Microbiol, Toronto, Japan, 21–25, May, 2007*; American Society for Microbiology: Washington, DC, USA, 2007; p. B-420.

24. Nanoukon, C.; Argemi, X.; Sogbo, F.; Orekan, J.; Keller, D.; Affolabi, D.; Schramm, F.; Riegel, P.; Baba-Moussa, L.; Prévost, G. Pathogenic features of clinically significant coagulase-negative staphylococci in hospital and community infections in Benin. *Int. J. Med. Microbiol.* **2017**, *307*, 75–82. [CrossRef] [PubMed]

25. Argemi, X.; Nanoukon, C.; Affolabi, D.; Keller, D.; Hansmann, Y.; Riegel, P.; Baba-Moussa, L.; Prévost, G. Comparative genomics and identification of an enterotoxin-bearing pathogenicity island SEPI-1/SECI-1, in *Staphylococcus epidermidis* Pathogenic Strains. *Toxins (Basel)* **2018**, *10*, E93. [CrossRef] [PubMed]

26. Madhusoodanan, J.; Seo, K.S.; Remortel, B.; Park, J.Y.; Hwang, S.Y.; Fox, L.K.; Park, Y.H.; Deobald, C.F.; Wang, D.; Liu, S.; et al. An Enterotoxin-bearing pathogenicity island in *Staphylococcus epidermidis*. *J. Bacteriol.* **2011**, *193*, 1854–1862. [CrossRef] [PubMed]

27. Chi, Y.L.; Sadler, I.; Jablonski, L.M.; Callantine, S.D.; Deobald, C.F.; Stauffacher, C.V.; Bohach, G.A. Zinc-mediated dimerization and Its effect on activity and conformation of staphylococcal enterotoxin type C. *J. Biol. Chem.* **2002**, *277*, 22839–22846. [CrossRef] [PubMed]

28. Schlievert, P.M.; Bohach, G.A.; Ohlendorf, D.H.; Stauffacher, C.V.; Leung, D.Y.; Murray, D.L.; Prasad, G.S.; Earhart, C.A.; Jablonski, L.M.; Chi, Y.L. Molecular structure of staphylococcus and streptococcus suerantigens. *J. Clin. Immunol.* **1995**, *15* (Suppl. 6), 4S–10S. [CrossRef] [PubMed]

29. Attien, P.; Sina, H.; Moussaoui, W.; Zimmermann-Meise, G.; Dadié, T.; Keller, D.; Riegel, P.; Edoh, V.; Kotchoni, S.O.; Dié, M.; et al. Mass spectrometry and multiplex antigen assays to assess microbial quality and toxin production of *Staphylococcus aureus* strains isolated from clinical and food samples. *Biomed. Res. Int.* **2014**, 485620. [CrossRef]

30. Li, S.J.; Hu, D.L.; Maina, E.K.; Shinagawa, K.; Omoe, K.; Nakane, A. Superantigenic activity of toxic shock syndrome toxin-1 is resistant to heating and digestive enzymes. *J. Appl. Microbiol.* **2011**, *110*, 729–736. [CrossRef] [PubMed]
31. Mera, S.; Tatulescu, D.; Cismaru, C.; Bondor, C.; Slavcovici, A.; Zanc, V.; Carstina, D.; Oltean, M. Multiplex cytokine profiling in patients with sepsis. *Apmis* 2011, 119, 155–163. [CrossRef] [PubMed]

32. Zhou, J.; Chaudhry, H.; Zhong, Y.; Ali, M.; Perkins, L.A.; Owens, W.; Morales, J.E.; McGuire, F.; Zumbrun, E.; Zhang, J.; et al. Dysregulation in microRNA expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathology. *Cytokine* 2015, 71, 89–100. [CrossRef] [PubMed]

33. Dinarello, C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. *Chest* 1997, 112, 321S–329S. [CrossRef] [PubMed]

34. Krakauer, T.; Pradhan, K.; Stiles, B.G. Staphylococcal superantigens spark host-mediated danger signals. *Front. Immunol.* 2016, 7, 1–14. [CrossRef] [PubMed]

35. Lamphear, J.G.; Bohach, G.A.; Rich, R.R. Structural dichotomy of staphylococcal enterotoxin C superantigens leading to MHC class II independent activation of T lymphocytes. *J. Immunol.* 1998, 160, 2107–2114. [PubMed]

36. Leder, L.; Llera, A.; Lavoie, P.M.; Lebedeva, M.I.; Li, H.; Sekaly, R.P.; Bohach, G.A.; Gahr, P.J.; Schlievert, P.M.; Karjalainen, K.; et al. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor- chain and major histocompatibility complex class II. *J. Exp. Med.* 1998, 187, 823–833. [CrossRef] [PubMed]

37. Rossle, S.C.; Bisch, P.M.; Lone, Y.C.; Abastado, J.P.; Kourilsky, P.; Bellio, M. Mutational analysis and molecular modeling of the binding of *Staphylococcus aureus* enterotoxin C2 to a murine T cell receptor V-10 chain. *Eur. J. Immunol.* 2002, 32, 2172–2178. [CrossRef] [PubMed]

38. Wang, X.; Zhang, H.; Xu, M.; Cai, Y.; Liu, C.; Su, Z.; Zhang, C. Biological characterization of the zinc site coordinating histidine residues of staphylococcal enterotoxin C2. *Microbiology* 2009, 155, 680–686. [CrossRef] [PubMed]

39. Bergdoll, M. *Staphylococcus aureus*. *Foodborne Pathog. Dis.* 1991, D1989, 463–524.

40. Orwin, P.M.; Leung, D.Y.; Tripp, T.J.; Bohach, G.A.; Earhart, C.A.; Ohlendorf, D.H.; Schlievert, P.M. Characterization of a novel staphylococcal enterotoxin-like superantigen, a member of the group V subfamily of pyrogenic toxins. *Biochemistry* 2002, 41, 14033–14040. [CrossRef] [PubMed]

41. Sanger, F.; Nicklen, S.; Coulson, A.R. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 1977, 74, 5463–5467. [CrossRef] [PubMed]

42. Translate. Available online: http://web.expasy.org/translate (accessed on 18 February 2017).

43. ProtParam. Available online: http://web.expasy.org/protparam (accessed on 21 January 2017).

44. Yang, J.; Yan, R.; Roy, A.; Xu, D.; Poisson, J.; Zhang, Y. The I-TASSER Suite: Protein structure and function prediction. *Nat. Methods* 2015, 12, 7–8. [CrossRef] [PubMed]

45. Podkowik, M.; Bystroń, J.; Bania, J. Genotypes, antibiotic resistance and virulence factors of staphylococci from ready-to-eat food. *Foodborne Pathog. Dis.* 2012, 9, 91–93. [CrossRef] [PubMed]

46. Meyer, F.; Girardot, R.; Piémont, Y.; Prévost, G.; Colin, D.A. Analysis of the specificity of Panton-Valentine leucocidin and gamma-hemolysin F component binding. *Infect. Immun.* 2009, 7, 266–273. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).